Home » Topics » Regulatory » EMA

EMA
RSS

Lutathera receives positive opinion from EMA for GEP-NETs

July 24, 2017

AbbVie's Humira receives positive opinion from EMA for uveitis

July 24, 2017

EMA committee backs approval of Janssen's Symtuza

July 24, 2017

EMA's CHMP grants positive opinion for dupixent for the treatment of atopic dermatitis

July 24, 2017

EMA committee recommends approval of label update for Lixiana

July 17, 2017

EMA validates pacritinib MAA for patients with myelofibrosis who have thrombocytopenia

July 14, 2017

Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA

July 14, 2017

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

July 7, 2017

RDD Pharma's RDD-0315 given orphan drug status in E.U.

July 7, 2017

Polatuzumab vedotin is eligible for access to EMA's PRIME program

June 30, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 10, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026